Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

serclutamab talirine (ABBV-321)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AbbVie

Drug class:

DNA replication inhibitor, EGFR-targeted antibody-drug conjugate

Related drugs:

LR004-VC-MMAE (5)

inotuzumab ozogamicin (28)

gemtuzumab ozogamicin (24)

idarubicin (22)

bendamustine (13)

loncastuximab tesirine-lpyl (7)

trastuzumab duocarmazine (6)

rovalpituzumab tesirine (5)

PF-06647263 (0)

LR004-VC-MMAE (5)

›

EGFR overexpression	Glioblastoma	EGFR overexpression	Glioblastoma	ABBV-321 Sensitive: C2 – Inclusion Criteria ABBV-321 Sensitive : C2	ABBV-321 Sensitive: C2 – Inclusion Criteria ABBV-321 Sensitive : C2
EGFR overexpression	Triple Negative Breast Cancer	EGFR overexpression	Triple Negative Breast Cancer	ABT 263 + ABBV-321 Sensitive: D – Preclinical ABT 263 + ABBV-321 Sensitive : D	ABT 263 + ABBV-321 Sensitive: D – Preclinical ABT 263 + ABBV-321 Sensitive : D
EGFR expression	Head and Neck Cancer	EGFR expression	Head and Neck Cancer	ABBV-321 Sensitive: D – Preclinical ABBV-321 Sensitive : D	ABBV-321 Sensitive: D – Preclinical ABBV-321 Sensitive : D
EGFR expression	Lung Cancer	EGFR expression	Lung Cancer	ABBV-321 Sensitive: D – Preclinical ABBV-321 Sensitive : D	ABBV-321 Sensitive: D – Preclinical ABBV-321 Sensitive : D
EGFR overexpression	Mesothelioma	EGFR overexpression	Mesothelioma	ABBV-321 Sensitive: D – Preclinical ABBV-321 Sensitive : D	ABBV-321 Sensitive: D – Preclinical ABBV-321 Sensitive : D
EGFR underexpression	Colorectal Cancer	EGFR underexpression	Colorectal Cancer	ABBV-321 Sensitive: D – Preclinical ABBV-321 Sensitive : D	ABBV-321 Sensitive: D – Preclinical ABBV-321 Sensitive : D